AGP Picks
View all

Hemlibra market seen gaining on rising hemophilia cases and treatment shifts

Nov. 4, 2026
Hemlibra market seen gaining on rising hemophilia cases and treatment shifts
By AI, Created 14:00 UTC, Nov 04, 2026, AGP -

The Business Research Company says the Hemlibra market is poised for continued expansion through 2035, driven by more hemophilia A diagnoses, higher healthcare spending, and demand for non-factor therapies. North America led the market in 2025, while Europe is projected to grow fastest.

Why it matters: - Hemlibra is positioned to benefit as hemophilia A treatment moves away from traditional factor VIII replacement and toward non-factor options. - Growth in diagnosed patients, especially those with inhibitors, expands the addressable market for emicizumab. - The market outlook matters for drugmakers, payers and care providers as home-based and subcutaneous treatment models gain traction.

What happened: - The Business Research Company released a Hemlibra market report covering market size, trends and a global forecast for 2026-2035. - The report says the Hemlibra market is attracting more attention as new therapies and improved diagnostics change hemophilia A treatment. - The report identifies rising global hemophilia prevalence, stronger adherence, higher healthcare spending and next-generation antibody innovation as major growth drivers. - The report also highlights a shift toward prophylactic care, long-acting treatments and better pediatric hemophilia management. - The report includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspot infographics, and updated graphics and tables. - Download a free sample of the Hemlibra market report. - View the full Hemlibra market report.

The details: - Hemlibra, also known as emicizumab, is a targeted therapy used to prevent or reduce bleeding episodes in people with hemophilia A. - Hemophilia A is caused by deficient or defective factor VIII, a protein needed for blood clotting. - Hemlibra is a bispecific monoclonal antibody that mimics factor VIII by linking activated factor IX and factor X to support clot formation. - The therapy is delivered by subcutaneous injection. - Dosing can be weekly, every two weeks or monthly. - The product is used in children and adults, including patients who have developed factor VIII inhibitors. - The report ties historical market growth to the limits of traditional factor VIII therapies, unmet need among patients with inhibitors, bispecific antibody advances, better detection of hemophilia A and strong clinical trial results. - The report says future growth should come from a larger global hemophilia population, broader home treatment adoption, better adherence, higher healthcare spending and next-generation antibody innovation. - In 2025, North America held the largest share of the global Hemlibra market. - Europe is projected to be the fastest-growing region during the forecast period. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - Pfizer reported in April 2025 that the UK hemophilia A and B patient population exceeded 11,800 in 2023/24. - The UK Office for National Statistics said total healthcare expenditure rose 5.6% in nominal terms from 2022 to 2023, after 0.9% growth the year before.

Between the lines: - The report reflects a broader industry push toward treatments that are easier to administer and more compatible with long-term prophylaxis. - Subcutaneous dosing and less frequent schedules can support adherence, which may help maintain demand even as competition increases. - Regional growth patterns suggest mature markets will keep generating volume, while Europe may offer the fastest expansion from a smaller base.

What's next: - The report expects the market to continue expanding through 2035 as diagnosis rates, treatment access and healthcare spending rise. - Hemlibra’s competitive position will likely hinge on how quickly non-factor and long-acting therapies gain adoption. - The company invites readers to speak with an expert for more information.

The bottom line: - Hemlibra’s market story is now about broader diagnosis, easier treatment delivery and a steady shift away from traditional factor replacement.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

LATAM Technology Reporter

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

LATAM Technology Reporter

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.